bluejaydx.com - BJDX Company Short-Term Debt

Bluejay Diagnostics, Inc. (BJDX) - corporate logo

The price action for Bluejay Diagnostics (BJDX) reflects the dynamics of a company whose blood rapid-test patents and stringent FDA requirements restrict competitor access. The current metric stands at 0.00, while liquidity risk and the anticipation of portable equipment certification exert pressure on capital. The business generates revenue from the supply of sepsis diagnostic systems, commanding a premium price for analysis speed in intensive care units.

BJDX (Bluejay Diagnostics, Inc.) Company Short-Term Debts history from 07/04/2022 to 10/28/2026

Bluejay Diagnostics Corp - analytical breakdowns and key metrics (BJDX)

- price and consensus price forecast:
Stock Price Bluejay Diagnostics, Inc.|BJDX - Analyst Consensus Forecast
- market capitalization data:
Market Value Bluejay Diagnostics, Inc.|BJDX - Business Value
- book capitalization data:
Book Value per Share Bluejay Diagnostics|BJDX - Book Capitalization|Market Value to Book Value Ratio bluejaydx.com|BJDX - Aggregate Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Bluejay Diagnostics|BJDX - Long-Term Liabilities to Capital|Short-Term Debt to Equity Bluejay Diagnostics|BJDX - Company Total Debt Obligations|Debts to Book Capitalization Bluejay Diagnostics, Inc.|BJDX - Long-Term Debt Volume|Company Short-Term Debt Bluejay Diagnostics
Analysis of all company metrics:Bluejay Diagnostics, Inc. BJDX
Finished products of Bluejay Diagnostics

This indicator measures total liabilities with a maturity of up to one year, reflecting the business's ability to manage liquidity and operational gaps. The short-term borrowing dynamics of Bluejay Diagnostics (BJDX) demonstrate a balance between the production costs of rapid tests in the US and available capital, which is critical for the uninterrupted supply of innovative sepsis diagnostic methods to intensive care units.

Competitor analysis for Bluejay Diagnostics

Agilent - Company Short-Term Debts|DGX: Company Short-Term Debts|Company Short-Term Debt Illumina Corp|Exact Sciences Inc. (EXAS) - Company Short-Term Indebtedness|RVTY (Revvity, Inc.) - Company Short-Term Debts|Company Short-Term Debts BIO|Company Short-Term Debt Anbio (NNNN)|Company Short-Term Debt Sotera Health Corp SHC|QDEL: Company Current Liabilities|OPKO Health Corp. - Short-Term Debt|Company Short-Term Debt CDNA (CareDx, Inc.)|MRVI - Short-Term Debt Volume|Fulgent Genetics - Company Short-Term Debts|LAB (Standard BioTools Inc) - Short-Term Debt Volume|CTKB: Company Short-Term Debt|Short-Term Debt Volume OraSure Corp|Company Short-Term Debts Exagen Inc. (XGN)|Company Short-Term Debt MDXH (mdxhealth.com)|Company Short-Term Debt Lucid Diagnostics LUCD|PRE - Company Short-Term Debt|Insight Molecular - Company Current Liabilities|TRIB - Company Short-Term Debts|Company Short-Term Debts PRPH|AIMD (ainos.com) - Short-Term Debt|Co-Diagnostics (CODX) - Company Short-Term Debt|Amount of Current Liabilities Heart Test Laboratories, Inc.|Company Short-Term Debts BMRA|Company Short-Term Debts cardiodiagnosticsinc.com CDIO|VRAX: Company Current Liabilities|AWH - Short-Term Debt|Company Current Liabilities Accelerate Diagnostics, Inc. (AXDX)|CNTG - Company Short-Term Loans and Borrowings|Company Short-Term Debts enzo.com|Fresh2 Group (FRES) - Company Short-Term Indebtedness|GENE: Company Short-Term Debts|Short-Term Debt Volume 23andme.com|Company Short-Term Debts PMD